Scarica l'app Stockscreener
22.40
1.68%
0.37
Dopo l'orario di chiusura:
23.00
0.60
+2.68%
Precedente Chiudi:
$22.03
Aprire:
$21.98
Volume 24 ore:
150.70K
Relative Volume:
0.64
Capitalizzazione di mercato:
$329.45M
Reddito:
-
Utile/perdita netta:
$-64.47M
Rapporto P/E:
-22.63
EPS:
-0.99
Flusso di cassa netto:
$-52.33M
1 W Prestazione:
+0.22%
1M Prestazione:
+39.30%
6M Prestazione:
-8.65%
1 anno Prestazione:
+215.40%
Intervallo 1D:
$21.80
$22.58
Intervallo di 1 settimana:
$20.92
$23.04
Portata 52W:
$4.00
$31.01
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Nome
Jasper Therapeutics Inc
Settore
Industria
Telefono
(650) 549-1400
Indirizzo
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-08-11 | Iniziato | CapitalOne | Overweight |
| 2022-02-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Iniziato | Credit Suisse | Outperform |
| 2021-10-21 | Iniziato | William Blair | Outperform |
| 2021-10-20 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-13 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Jasper Therapeutics Inc Borsa (JSPR) Ultime notizie
Urticaria Clinical Trial Pipeline Accelerates: 20+ Leading Companies Pioneering New Treatments | DelveInsight - GlobeNewswire
JSPRJasper Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Long Term Trading Analysis for (JSPR) - Stock Traders Daily
Jasper Therapeutics' SWOT analysis: briquilimab stock shows promise amid challenges - Investing.com
Jasper Therapeutics (NASDAQ:JSPR) Earns Buy Rating from HC Wainwright - MarketBeat
Jasper Therapeutics to Present Preclinical Briquilimab Data - GlobeNewswire
Jasper Therapeutics to Present Preclinical Briquilimab Data at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting - StockTitan
Jasper Therapeutics Announces Further Expansion of Clinical Program in Chronic Spontaneous Urticaria - GlobeNewswire
Molina Healthcare (MOH) Set to Announce Earnings on Wednesday - Defense World
Analysts Set Rush Street Interactive, Inc. (NYSE:RSI) Target Price at $11.17 - Defense World
Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $74.86 Consensus Target Price from Brokerages - MarketBeat
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances - Citeline
Jasper Therapeutics (NASDAQ:JSPR) Rating Reiterated by HC Wainwright - Defense World
Metagenomi (NASDAQ:MGX) Stock Rating Reaffirmed by HC Wainwright - Defense World
JMP Securities Reiterates Market Outperform Rating for Jasper Therapeutics (NASDAQ:JSPR) - Defense World
JMP Securities analysts initates a Mkt outperform rating for Jasper Therapeutics Inc (JSPR) - Knox Daily
Analysts review Ares Capital Corp’s rating - Knox Daily
Jasper Therapeutics shares keep buy rating with positive study results By Investing.com - Investing.com Canada
DoubleVerify Holdings Inc [DV] stock was sold by Allais Nicola T at the price of US$30365.0 - Knox Daily
When (JSPR) Moves Investors should Listen - Stock Traders Daily
Jasper Therapeutics Inc (JSPR) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Jasper gains 11% on data for briquilimab in urticaria (NASDAQ:JSPR) - Seeking Alpha
Jasper Therapeutics shares hold as Oppenheimer maintains $80 target By Investing.com - Investing.com Canada
Jasper Therapeutics shares hold as BTIG maintains $90 target By Investing.com - Investing.com UK
You Should Read This Analysis Before Investing in Jasper Therapeutics Inc (NASDAQ:JSPR) - US Post News
Why Is Fatty-Liver Drug Developer Inventiva Stock Trading Higher On Monday? - Yahoo Finance
Jasper reports promising early results in urticaria study - Investing.com
Why Is Chronic Disease-Focused Jasper Therapeutics Stock Trading Higher On Monday? - Benzinga
Jasper Therapeutics Stock Gains on Strong Briquilimab Trial Results - MarketWatch
Jasper Therapeutics Reports Positive Data from SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria - GlobeNewswire
Jasper reports promising early results in urticaria study By Investing.com - Investing.com UK
American Century Companies Inc. Has $320,000 Stock Holdings in Arcos Dorados Holdings Inc. (NYSE:ARCO) - Defense World
American Century Companies Inc. Grows Position in Hippo Holdings Inc. (NYSE:HIPO) - Defense World
Novavax (NASDAQ:NVAX) versus Jasper Therapeutics (NASDAQ:JSPR) Critical Contrast - Defense World
Jasper Therapeutics' SWOT analysis: briquilimab's potential in mast cell diseases - Investing.com India
Oppenheimer maintains Outperform rating on Jasper Therapeutics shares By Investing.com - Investing.com Canada
8,750 Shares in Sunrun Inc. (NASDAQ:RUN) Bought by Point72 Asia Singapore Pte. Ltd. - Defense World
Susquehanna Fundamental Investments LLC Invests $23.60 Million in Light & Wonder, Inc. (NASDAQ:LNW) - Defense World
1832 Asset Management L.P. Buys 1,538 Shares of Vanguard Total Stock Market ETF (NYSEARCA:VTI) - Defense World
Fanconi Anemia Market Expected to Experience Major Growth - openPR
Fanconi Anemia Market Expected to Experience Major Growth by 2034, According to DelveInsight | Novartis, Foresee Pharma, Rocket Pharma, Jasper Therapeutics - The Globe and Mail
Jasper Therapeutics (NASDAQ:JSPR) Rating Reiterated by JMP Securities - MarketBeat
Benjamin F. Edwards & Company Inc. Decreases Stock Holdings in Hartford Schroders Tax-Aware Bond ETF (NYSEARCA:HTAB) - Defense World
Jasper Therapeutics Inc [JSPR] Shares Jump Approximately 156.76% Over the Year - Knox Daily
Insider Selling: Kabot Brian, Momentus Inc [MNTS] Director divested 400 shares - Knox Daily
Jasper Therapeutics Inc (JSPR) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Jasper Therapeutics Inc’s Market Journey: Closing Weak at 18.23, Down -16.34 - The Dwinnex
Jasper concerns driven by Celldex data ‘overdone,’ says Stifel - TipRanks
Front Street Capital Management Inc. Sells 4,073 Shares of Kimball Electronics, Inc. (NASDAQ:KE) - Defense World
First Light Asset Management LLC Sells 482 Shares of Simulations Plus, Inc. (NASDAQ:SLP) - Defense World
Booz Allen Hamilton Holding Co. (NYSE:BAH) Shares Acquired by Providence Capital Advisors LLC - Defense World
Jasper Therapeutics Inc Azioni (JSPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.02%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):